Articles

An analysis found that commercial health insurers do not issue coverage policies more quickly for specialty drugs approved through FDA-expedited review programs Read More ›

Claims-based analysis assesses healthcare resource utilization and standard-of-care costs among US patients with relapsed or refractory MCL Read More ›

Analysis of existing frameworks provides a foundation for data collection to inform patient-centered value and health technology assessment Read More ›

Systematic literature review finds substantial variability in patient characteristics and response rates across DLBCL trials Read More ›

Medicare Advantage claims analysis explores economic burden of cancer by type and stage, underscoring the importance of early detection Read More ›

Analysis of health plans examines the variability in specialty drug coverage among medical and pharmacy benefit policies Read More ›

Analysis of clinical practice guidelines identified 10 good practice recommendations for engaging patients in the development process Read More ›

Analysis of circulating tumor DNA can identify patients at high risk of early disease progression who could benefit from combining immune checkpoint inhibitors with chemotherapy. Read More ›

A highly multiplexed proteomic assay was developed to guide treatment selection for patients with lung cancer. Read More ›

Implementing a machine learning–based system that integrates radiologic, pathologic, and genomic data to predict response to PD-1 blockade may be able to outperform conventional unimodal approaches. Read More ›